Signant’s RTSM Manages Clinical IP Dispensation in Schizophrenia Study

Date Published:
Case Study

A pharmaceutical company needed to ensure proper dispensation of their investigational product (IP) around variable visit schedules across multiple patient subgroups, as well as ensure each patient had sufficient doses to last until their next visit without incurring waste. The company selected our Signant SmartSignals RTSM solution to help:

  • Maintain study balance across multiple strata and subgroups
  • Prevent IP allocation to duplicate subjects
  • Manage the return and destruction of supplies in all cases as needed, including early patient termination

Download the case study below and visit our RTSM page to learn more.

Learn More